MediWound (MDWD) Receiving Somewhat Positive News Coverage, Accern Reports
News stories about MediWound (NASDAQ:MDWD) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MediWound earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.9967586552683 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound Weighing an Appeal (feeds.benzinga.com)
- MediWound Ltd. (MDWD) Scheduled to Post Quarterly Earnings on Thursday (americanbankingnews.com)
- Zacks: Analysts Expect MediWound Ltd. (MDWD) to Post -$0.19 Earnings Per Share (americanbankingnews.com)
- MediWound to Host Third Quarter 2017 Financial Results Conference Call on November 16, 2017 at 8:30 a.m. Eastern Time (finance.yahoo.com)
- MediWound Ltd. (MDWD) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
Shares of MediWound (NASDAQ MDWD) opened at $4.30 on Tuesday. MediWound has a one year low of $4.25 and a one year high of $8.25.
Several research firms have weighed in on MDWD. ValuEngine raised MediWound from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. Oppenheimer Holdings, Inc. set a $10.00 price objective on MediWound and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Zacks Investment Research raised MediWound from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Wednesday, October 4th. Cowen and Company began coverage on MediWound in a research report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $10.00 price objective on shares of MediWound in a research report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.15.
TRADEMARK VIOLATION WARNING: “MediWound (MDWD) Receiving Somewhat Positive News Coverage, Accern Reports” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/14/mediwound-mdwd-receiving-somewhat-positive-news-coverage-accern-reports.html.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.